{
    "clinical_study": {
        "@rank": "25213", 
        "acronym": "SPIRE-LL", 
        "arm_group": [
            {
                "arm_group_label": "PF-04950615", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multicenter, double-blind, randomized study to access the efficacy, safety\n      and tolerability of PF-04950615 in subjects with hyperlipidemia receiving background statin\n      therapy."
        }, 
        "brief_title": "Randomized Clinical Trial of RN316 (PF-04950615) inSubjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events.", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Treated with a statin\n\n          -  Fasting LDL-C >=100 mg/dL and triglyceride <= 400 mg/dL\n\n          -  High or very high risk of incurring a cardiovascular event\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding females\n\n          -  Cardiovascular or cerebrovascular event or procedure within 90 days\n\n          -  Congestive heart failure NYHA class IV\n\n          -  Poorly controlled hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "939", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100514", 
            "org_study_id": "B1481045"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-04950615", 
                "description": "150 mg every 2 weeks, subcutaneous injection for 52 weeks.", 
                "intervention_name": "PF-04950615", 
                "intervention_type": "Drug", 
                "other_name": "RN316"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Subcutaneous injection every 2 weeks for 52 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary hyperlipidemia or mixed dyslipidemia", 
            "high risk of cardiovascular events", 
            "multiple cardiovascular disease risk factors."
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481045&StudyName=Randomized%20Clinical%20Trial%20of%20RN316%20%28PF-04950615%29%20inSubjects%20With%20Primary%20Hyperlipidemia%20or%20Mixed%20Dyslipidemia%20At%20Risk%20Of%20Cardiovascular%20"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 52 Week, Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability Of PF-04950615 in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events.", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fasting Low Density Lipoprotein Cholesterol (LDL-C)", 
            "measure": "Percent Change from Baseline in fasting LDL-C at week 12.", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percent change in fasting Total Cholesterol (TC), Apolipoprotein B (Apo B), non HDL-C, LDL-C by TG level (<or>=200 mg/dL), Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.", 
                "measure": "Change from baseline in fasting Lipid Parameters at Week 12.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "description": "Percent change in fasting Total Cholesterol (TC), Apolipoprotein B (Apo B), non HDL-C, LDL-C by TG level (<or>=200 mg/dL), Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.", 
                "measure": "Change from baseline in fasting Lipid Parameters at Week 24.", 
                "safety_issue": "No", 
                "time_frame": "week 24"
            }, 
            {
                "description": "Percent change in fasting Total Cholesterol (TC), Apolipoprotein B (Apo B), non HDL-C, LDL-C by TG level (<or>=200 mg/dL), Lipoprotein (a) (Lp(a), High Density Lipoprotein (HDL), Triglyceride, ApoA-I, and ApoA-II blood concentrations.", 
                "measure": "Change from baseline in fasting Lipid Parameters at Week 52.", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 12", 
                "measure": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 12.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 24.", 
                "measure": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 24.", 
                "safety_issue": "No", 
                "time_frame": "week 24"
            }, 
            {
                "description": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 52", 
                "measure": "Proportion of subjects achieving fasting LDL-C <=100 mg/dL and <=70 mg/dL at week 52.", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }, 
            {
                "description": "Plasma PF-04950615 concentration at week 12", 
                "measure": "Plasma PF-04950615 concentration at week 12.", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "description": "Plasma PF-04950615 concentration at week 24", 
                "measure": "Plasma PF-04950615 concentration at week 24.", 
                "safety_issue": "No", 
                "time_frame": "week 24"
            }, 
            {
                "description": "Plasma PF-04950615 concentration at week 52", 
                "measure": "Plasma PF-04950615 concentration at week 52.", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}